TW200510424A - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction

Info

Publication number
TW200510424A
TW200510424A TW093121513A TW93121513A TW200510424A TW 200510424 A TW200510424 A TW 200510424A TW 093121513 A TW093121513 A TW 093121513A TW 93121513 A TW93121513 A TW 93121513A TW 200510424 A TW200510424 A TW 200510424A
Authority
TW
Taiwan
Prior art keywords
treatment
sexual dysfunction
male sexual
ejaculation
relates
Prior art date
Application number
TW093121513A
Other languages
English (en)
Inventor
Christopher Peter Wayman
Rachel Jane Russell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200510424A publication Critical patent/TW200510424A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
TW093121513A 2003-07-23 2004-07-19 Treatment of male sexual dysfunction TW200510424A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
TW200510424A true TW200510424A (en) 2005-03-16

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093121513A TW200510424A (en) 2003-07-23 2004-07-19 Treatment of male sexual dysfunction

Country Status (12)

Country Link
EP (1) EP1656183B1 (zh)
JP (1) JP2006528171A (zh)
AT (1) ATE380048T1 (zh)
BR (1) BRPI0412255A (zh)
CA (1) CA2533177A1 (zh)
CL (1) CL2004001702A1 (zh)
GB (1) GB0317227D0 (zh)
MX (1) MXPA05014200A (zh)
TW (1) TW200510424A (zh)
UA (1) UA79674C2 (zh)
WO (1) WO2005006899A1 (zh)
ZA (1) ZA200505957B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
ATE412648T1 (de) * 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
CA2533177A1 (en) 2005-01-27
CL2004001702A1 (es) 2005-05-13
ZA200505957B (en) 2006-11-29
EP1656183A1 (en) 2006-05-17
WO2005006899A1 (en) 2005-01-27
GB0317227D0 (en) 2003-08-27
MXPA05014200A (es) 2006-07-03
JP2006528171A (ja) 2006-12-14
BRPI0412255A (pt) 2006-09-19
EP1656183B1 (en) 2007-12-05
ATE380048T1 (de) 2007-12-15
UA79674C2 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
HK1088004A1 (en) 3-heterocyclyl-azetidine compounds useful as nk1/nk2 receptors antagonists
ZA200702209B (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
HK1071355A1 (en) Process for the distillation of a mixture of isomeric diisocyanatodiphenylmethanes
TNSN07195A1 (en) Potentiators of glutamate receptors
HK1112002A1 (en) Humanized anti-beta7 antagonists and uses therefor
PL372820A1 (en) Method for the telomerisation of non-cyclic olefins
WO2007014263A3 (en) Octahydroisoquinoline compounds as opioid receptor modulators
HK1091200A1 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
TW200420543A (en) Treatment of female sexual dysfunction
WO2004056763A3 (en) Novel glucagon antagonists
HK1077827A1 (en) Diazabicyclononane and-decane derivatives their use as opioid receptor ligands
TW200510424A (en) Treatment of male sexual dysfunction
WO2002100350A3 (en) Dopamine receptor ligands and therapeutic methods based thereon
EA200801591A1 (ru) Антагонисты мускаринового рецептора
MXPA05012572A (es) Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central.
WO2006032994A3 (en) Muscarinic receptor antagonists
WO2004103289A3 (en) Driverse thyroid hormone receptor antagonists and uses thereof
MX2010006101A (es) Compuestos de triazol [4,5-d] pirimidina para tratamiento de aneurismas aorticas abdominales.
EP1619499A4 (en) NEW SCREENING METHOD
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia
TW200700727A (en) Screen